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ABSTRACT: The biodistribution, metabolism, cellular targeting, and gene expression of
a nonviral peptide DNA gene delivery system was examined. 125I-labeled plasmid DNA
was condensed with low molecular weight peptide conjugates and dosed i.v. in mice to
determine the influence of peptide DNA formulation parameters on specific gene tar-
geting to hepatocytes. Optimal targeting to hepatocytes required the combined use of a
triantennary glycopeptide (Tri-CWK18) and a polyethylene glycol-peptide (PEG-
CWK18) to mediate specific recognition by the asialoglycoprotein receptor and to reduce
nonspecific uptake by Kupffer cells. Tri-CWK18/PEG-CWK18 DNA co-condensates were
stabilized and protected from metabolism by glutaraldehyde crosslinking. An optimized
formulation targeted 60% of the dose to the liver with 80% of the liver targeted DNA
localized to hepatocytes. Glutaraldehyde crosslinking of DNA condensates reduced the
liver elimination rate from a t1/2 of 0.8 to 3.6 h. An optimized gene delivery formulation
produced detectable levels of human a1-antitrypsin in mouse serum which peaked at
day 7 compared to no expression using control formulations. The results demonstrate
the application of formulation optimization to improve the targeting selectivity and
gene expression of a peptide DNA delivery system. © 2000 Wiley-Liss, Inc. and the American
Pharmaceutical Association J Pharm Sci 89: 499–512, 2000
INTRODUCTION
Nonviral gene delivery relies on the use of carrier
molecules to bind plasmid DNA and mediate cell-
specific uptake of the DNA carrier complex.1–6
The efficiency of an intravenously dosed nonviral
gene delivery dosage form is dependent on the
DNA carrier complex to overcome obstacles that
prevent it from arriving at the target cell. De-
pending on the size and charge of a DNA complex,
it may be opsonized and entrapped in the capil-
lary beds of the lung or may be phagocytosed by
liver Kupffer cells or spleen macrophages.7 The
DNA carrier complex must possess sufficient se-
rum stability to remain intact during circulation
since premature dissociation exposes unprotected
DNA resulting in rapid metabolism by serum en-
donucleases.8 Once endocytosed by target cells,
the DNA carrier complex must also escape degra-
dative pathways and target the nucleus.7
In the absence of a carrier molecule, 60–70% of
i.v. dosed plasmid DNA is taken up by scavenger
receptors on liver Kupffer cells.8,9 To facilitate se-
lective targeting to hepatocytes, ligands for the
asialoglycoprotein receptor (ASGP-R) have been
incorporated into carrier molecules.1,2,10–18 One of
the first carriers was a conjugate of high molecu-
lar weight (HMW) polylysine440 covalently linked
to asialoorosomucoid (ASOR),11 a glycoprotein
possessing terminal galactose residues on its N-
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glycans. Following i.v. dosing, ASOR-polylysine
DNA condensates were also rapidly taken up by
liver and then slowly eliminated with t1/2 of 1.3 h
due to the metabolic protection provided by poly-
lysine.11 To further extend the liver half-life of
DNA and the duration of gene expression,
Chowdhury et al. performed partial hepatectomy
following the delivery of ASOR-polylysine DNA
condensates to rats.12 Since lysosomal trafficking
is dramatically decreased following partial hepa-
tectomy, the rate of DNA metabolism was also
decreased resulting in the recovery of 9% of the
dose in the liver after 24 h.
Refinements in carrier design have resulted in
the replacement of ASOR-polylysine with lacto-
sylated and galactosylated polylysine.13,14 Per-
ales et al. examined the ability of a galactosylated
polylysine100 to mediate liver targeting and re-
ported the PCR detection of DNA in the liver for
32 days but did not attempt to determine cell-type
specific targeting.14 Recent studies by Hashida et
al. utilized galactosylated polylysine100 as a car-
rier to establish that 70% of the liver targeted
DNA resides in hepatocytes.15,16 Opsonization of
the DNA carrier complex could be minimized by
controlling the polylysine DNA stoichiometry to
create electronegative DNA complexes; however,
this approach is unlikely to allow DNA targeting
to peripheral sites since electronegative DNA con-
densates are also taken up nonspecifically by liver
Kupffer cells.15,16
An alternative approach to increase the resis-
tance of polylysine DNA condensates to opsoniza-
tion is to incorporate polyethylene glycol (PEG)-
polylysine to shield the surface charge of DNA
condensates.19–21 Thus far, only one study has
examined the utility of PEGylated ASOR-poly-
lysine100 as a DNA carrier for i.v. dosed formula-
tions and found that PEG decreased the aggrega-
tion of DNA condensates but failed to influence
the in vivo biodistribution.22
It is now clear that optimizing a gene delivery
formulation will require deriving correlations be-
tween the physico-chemical properties of the DNA
carrier complex and in vivo parameters such as
biodistribution, cell-type targeting specificity,
metabolism and elimination, and gene expres-
sion.22 To do so requires the complete synthetic
control over the design of carrier molecules which
can only be achieved by reducing their molecular
weight. Consequently, the utility of derivatized
HMW polylysine as a condensing agent to opti-
mize gene expression is inadequate since it leads
to increased heterogeneity and does not allow pre-
cise control over the location or stoichiometry of
ligand or PEG attachment.22 Properly designed
LMW DNA carriers will not only eliminate het-
erogeneity but can also be systematically opti-
mized to reduce or eliminate toxicity.23 Therefore,
it is essential to determine if low molecular
weight (LMW) carriers can be designed to replace
HMW polylysine conjugates as i.v. dosed nonviral
gene delivery systems.
To test this hypothesis, we propose the use of
two well-defined LMW carriers that can be ad-
mixed to allow the ratio of targeting ligand and
PEG on DNA condensates to be systematically
optimized. The LMW carriers used in the present
study are derivatives of a synthetic peptide, Cys-
Trp-Lys18 (CWK18), which forms small (<100 nm)
DNA condensates capable of mediating efficient
nonspecific gene transfer to cells in culture.24–26
To endow the delivery system with targeting
specificity, a natural triantennary N-glycan li-
gand has been covalently attached to the side
chain of cysteine in CWK18 resulting in a trian-
tennary glycopeptide (Tri-CWK18) that binds to
the ASGP-R with a nM dissociation constant.27,28
We have also recently reported the synthesis and
formulation of PEG-CWK18 DNA condensates
that mask the surface charge of DNA condensates
and reduce nonspecific interactions with cells.29
Additionally, the stability of LMW peptide DNA
condensates has been greatly improved by use of
glutaraldehyde as a crosslinking agent that both
slows DNA metabolism and alters the in vitro
transient gene expression profile.30
Here we report the in vivo analysis of glutar-
aldehyde crosslinked DNA co-condensates pre-
pared with Tri-CWK18 and PEG-CWK18 to sys-
tematically optimize DNA targeting to hepato-
cytes via the ASGP-R. The relationships derived
between physiochemical properties and biodistri-
bution provide insight into formulation param-
eters to improve the level of transient gene ex-
pression in vivo.
MATERIALS AND METHODS
Sodium 125iodide was purchased from Dupont
NEN (Boston, MA). Heparin, D-mannitol, bovine
serum albumin, Hepes, collagenase from Clos-
tridium histolyticum type IV (lot number:
47H6865), carbonyl iron, 70% glutaraldehyde,
2,28-azion-bis(3-ethylbenzthiaxoline-6-sulfonic
acid (ABTS), Tween 20, anti-human a-1-antitryp-
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sin IgG from goat and rabbit, and human a-1-
antitrypsin were purchased from Sigma (St.
Louis, MO). Zeta probe cationic membranes were
purchased from Bio-Rad (Hercules, CA). Agarose
was purchased from Gibco-BRL (Gaithersburg,
MD). Methoxy-PEG-vinylsulfone (5,000 Da) was
purchased from Fluka (Ronkonkoma, NY). Keta-
mine hydrochloride was purchased from Fort
Dodge Laboratories (Fort Dodge, IA). Xylazine
hydrochloride was purchased from Miles Inc.
(Shawnee Mission, KS). Silastic catheters (0.305
mm inner diameter × 0.635 mm outer diameter)
were purchased from Baxter (Obetz, OH). ICR
mice (30–35 g) were purchased from Harlan (In-
dianapolis, IN) and housed in cages located in a
limited access area maintaining a 12-h light–dark
cycle and controlled temperature (26–28°C).
b-Galactosidase from bovine testes (EC 3.2.1.23)
and anti-rabbit IgG-peroxidase from goat were
purchased from Boehringer Mannheim (India-
napolis, IN). Ultrapure 100 and tip100, DNA pu-
rification columns were purchased from Qiagen
(Santa Clarita, CA). Analytical and semi-
preparative HPLC columns were purchased from
Vydac (Hesperia, CA).
Radiolabeling Plasmid DNA
Endotoxin-free plasmid DNA encoding human
a-1-antitrypsin (hAAT) driven by a cytomegalo-
virus promoter (pCMVhAAT)31 was purified
from Escherichia coli using a Qiagen ultrapure
column according to the manufacturers instruc-
tions. Plasmid DNA was radiolabeled with 125I
as described previously resulting in supercoiled
and circular DNA with specific activity of 200
nCi/mg.32
Glycopeptide and PEG–Peptide Synthesis
CWK18 was prepared and alkylated with iodoace-
tic acid to form AlkCWK18 as described previ-
ously.24 A triantennary N-glycan was purified
from bovine fetuin as the Boc-tyrosine deriva-
tive.33 The oligosaccharide was converted to an
iodoacetylated tyrosinamide oligosaccharide and
then reacted with CWK18 to form Tri-CWK18.
27
Agalactosyl Tri-CWK18 was prepared by treating
400 nmol of Tri-CWK18 with 4 mU of b-galactosi-
dase in 5 mM citrate phosphate, pH 4.3, at 37°C
for 24 h. The glycopeptide was purified by inject-
ing 50 nmol on an analytical RP-HPLC column
(0.47 × 25 cm) eluted at 1 mL/min with 0.1% TFA
and a gradient of acetonitrile from 5% to 25% over
30 min. The product peak eluting at 20 min was
collected and freeze-dried. The complete removal
of galactose from the purified glycopeptide was
confirmed using ES–MS, 1H NMR, and monosac-
charide composition analysis.27 Polyethylene gly-
col vinyl sulfone (PEG-VS) was reacted with
CWK18 to prepare PEG-CWK18—which was puri-
fied and characterized as reported previously.29
Formulation of Crosslinked Glycopeptide and
PEG–Peptide DNA Co-condensates
Tri-CWK18, PEG-CWK18, or AlkCWK18 (250 mL
of 40 nmol/mL in HBM, composed of 5 mM Hepes,
0.27 M mannitol, pH 7.4) were combined with 250
mL of 100 mg/mL pCMVhAAT while vortexing.
DNA condensates formed instantly but were al-
lowed to equilibrate for 30 min prior to analyzing
particle size and zeta potential on a Zeta-Plus
(Brookhaven Instruments, Holtsville, NY). DNA
co-condensates were prepared by mixing Tri-
CWK18 with PEG-CWK18 at either 50:50, 10:90,
or 2:98 mol % (Tri-CWK18:PEG-CWK18) to form
40 nmol/mL admixtures used to condense DNA as
described above.
Glutaraldehyde crosslinked DNA condensates
were formed by adding 60 or 150 nmol of glutar-
aldehyde (6 or 15 mol eq of glutaraldehdye per
mol of CWK18) to 500 mL of 50 mg/mL preformed
DNA condensates, followed by reaction for 24 h at
4°C.30 The stability of crosslinked DNA conden-
sates were evaluated by adjusting 200 mL ali-
quots (10 mg DNA) to 0.3, 0.5, 1.0, and 1.5 M so-
dium chloride (normalized to 300 mL) followed by
sonication for 30 s with a 100 W Microson XL-
2000 ultrasonic probe homogenizer (Kontes, Vine-
land, NJ) with a vibrational amplitude of 5 to
fragment uncondensed DNA.30 DNA condensates
(0.5 mg) were digested for 12 h at 37°C with 40 mg
of trypsin and then electrophoresed on an agarose
gel and visualized by ethidium bromide staining.
Crosslinked Tri-CWK18/PEG-CWK18 DNA co-
condensates (50 mg in 1 mL) were dialyzed for 75
h in a fixed volume dialyzer against a 100,000
MWCO membrane to remove unbound peptides.
DNA co-condensates (25 mg) in the retentate were
then hydrolyzed in 4 N hydrochloric acid at 100°C
for 5 h to release glucosamine from Tri-CWK18.
The samples were dried and reconstituted in 200
mL of water, and a 40-mL aliquot was analyzed by
high-pH anion-exchange chromatography rela-
tive to a glucosamine standard.34 Comparison of
the glucosamine recovered before and after dialy-
sis allowed quantification of the percent of Tri-
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CWK18 incorporated into crosslinked DNA co-
condensates.
Pharmacokinetic Analysis of DNA Condensates.
Mice were anesthetized by i.p. injection of keta-
mine hydrochloride (100 mg/kg) and xylazine hy-
drochloride (10 mg/kg) and then underwent a
dual cannulation of the right and left jugular
veins. An i.v. dose of 125I-DNA (5 mg in 50 mL of
HBM, 1.2 mCi) or 125I-DNA condensate (5 mg) was
administered via the left catheter, and blood
samples were drawn from the right catheter at 1,
3, 6, 10, 15, 20, 30, 40, and 60 min, then replaced
with 10 mL of normal saline. The amount of ra-
dioactivity in each blood time point was quanti-
fied by direct g-counting followed by extraction of
the DNA and analysis by gel electrophoresis as
described below. Blood time points (10 mL) were
digested with proteinase K (500 mL of 0.5 mg/mL
proteinase K in 100 mM sodium chloride, 1%
SDS, and 50 mM Tris-HCl, pH 8.0) for 12 h at
37°C. DNA was extracted with 500 mL of phenol/
chloroform/isoamyl alcohol (24:25:1) and then
precipitated with 1 mL of ethanol and centrifuged
at 13,000g for 15 min. The DNA pellet was air-
dried, dissolved in 10 mL of Tris-EDTA buffer, and
g-counted, and then the entire sample was loaded
and electrophoresed for 1 h at 70 V on an 1%
agarose gel. The gel was dried on a zeta probe
membrane and autoradiographed on a Phosphor
Imager (Molecular Devices, Sunnyvale CA) fol-
lowing a 15-h exposure.
Biodistribution Analysis of 125I-DNA and
125I-DNA Condensates
Mice were anesthetized, and a single catheter was
placed in the right jugular vein. 125I-DNA (2.5 mg
in 50 mL of HBM, 0.6 mCi) or 125I-DNA conden-
sates were i.v. dosed followed by vein ligation. Af-
ter 5, 15, 30, 60, or 120 min, mice were sacrificed
by cervical dislocation and the major organs
(liver, lung, spleen, stomach, kidney, heart, large
intestine, and small intestine) were harvested,
rinsed with saline, and weighed. The radioactiv-
ity in each organ was determined by direct
g-counting and expressed as the targeting effi-
ciency, defined as the percent of the dose in the
target organ.
Isolation of Hepatocytes and Kupffer Cells
Mice were i.v. dosed in the tail vein with 20 mg of
carbonyl iron in 0.2 mL of saline. After 45 min,
mice were anesthetized and a single catheter was
inserted into the right jugular vein and used to
dose 125I-DNA or 125I-DNA condensates (2.5 mg
DNA in 50 mL, 0.6 mCi in HBM). Following 30 min
of biodistribution, the portal vein was cannulated
and used to administer 0.2 mL of heparin (100
U/mL) followed immediately by the perfusion
buffers. The liver was first perfused at 5 mL/min
for 2 min with oxygenated (95% oxygen, 5% car-
bon dioxide) preperfusion buffer (calcium- and
magnesium-free Hepes solution, pH 7.45, 37°C),
and then at 3 mL/min for an additional 3 min. The
liver was digested by perfusion with oxygenated
Seglen’s Buffer (pH 7.45, 37°C) containing 0.058%
(w/v) collagenase type IV at 3 mL/min for 16–20
min. At the start of the perfusion, the vena cava
and aorta were cut, and at the completion, the
liver was excised, placed in a Petri dish (4°C), and
cut into small pieces. Cells were dislodged and
dispersed in ice-cold Hank’s solution containing
10 mM Hepes, pH 7.45, 0.1% BSA, and then in-
cubated at 37°C for 20 min with shaking (30 rev/
min). The dispersed cells were passaged through
a 73-mm mesh filter then transferred to a 35-mL
glass tube. The iron-filled Kupffer cells were at-
tracted to the wall of the tube with a magnet
while other cells were decanted off. The procedure
was repeated three times, and the Kupffer cells
were combined and resuspended in 0.8 mL of
Hank’s Hepes Buffer. The remaining cell suspen-
sion was centrifuged at 50g for 1 min and the
supernatant was discarded. The pelleted hepato-
cytes were washed twice with ice-cold Hank’s-
Hepes buffer followed by centrifuging at 50g for 1
min. The hepatocytes were re-suspended in 2 mL
of Hank’s-Hepes buffer and the cell number and
viability were determined by the trypan blue dye-
exclusion method. The amount of radioactivity as-
sociated with each cell fraction was determined
by g-counting.
In Vivo Gene Expression
Mice were dosed in the tail vein by infusing 1 mL
of HBM containing either 50 mg of plasmid DNA
(30 mice), 50 mg of crosslinked agalactosyl-Tri-
CWK18/PEG-CWK18 (10:90) DNA co-condensates
(30 mice) or 50 mg of crosslinked Tri-CWK18/PEG-
CWK18 (10:90) DNA co-condensates (60 mice).
Blood (1 mL) was collected via the jugular artery
from 3–6 mice per day for 10 days after dosing.
The blood was allowed to clot at room tempera-
ture and centrifuged at 13,000g for 15 min, and
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the serum that was collected was stored frozen at
−20°C until assayed by ELISA.
A modified double-antibody sandwich ELISA
was used to determine the magnitude of hAAT
gene expression.35 After each incubation, the
wells were washed three times with phosphate-
buffered saline, pH 7.4, containing 0.05% Tween
20 (PBS-Tween). The goat anti-hAAT primary an-
tibody was diluted 1:1000 in 0.1 M sodium bicar-
bonate, pH 9.6, and 100 mL was added to each
well and incubated overnight at 4°C. Nonspecific
binding was blocked with 100 mL of 5 w/v % non-
fat dry milk in PBS incubated for 1 h at 37°C.
Mouse serum samples (100 mL) or hAAT primary
standards added to mouse serum were added to
each well and allowed to bind for 2 h at 37°C. The
rabbit anti-hAAT secondary antibody (diluted 1:
1000 in PBS-Tween) was added (100 mL) to each
well followed by incubation at 37°C for 2 h. Anti-
rabbit peroxidase conjugated antibody (diluted 1:
1000 in PBS-Tween) was added (100 mL) and al-
lowed to bind for 2 h at room temperature. Fi-
nally, substrate solution (100 mL of 1 mg/mL
ABTS in 0.2 M sodium phosphate, pH 7.6, with
0.003% hydrogen peroxide) was added and incu-
bated at RT for 30 min prior to reading the ab-
sorbance at 415 nm on a Bio-Rad 550 microplate
reader. The amount of hAAT expressed was de-
termined from a standard curve prepared from
the addition of hAAT to mouse serum.
RESULTS
Tri-CWK18, PEG-CWK18, and AlkCWK18 were
prepared and used as LMW DNA carrier mol-
ecules (Figure 1). The terminal galactose residues
of Tri-CWK18 were removed with b-galactosidase
to create agalactosyl-Tri-CWK18 as a negative
control for ASGP-R recognition. 1H NMR, ES–
MS, and monosaccharide compositional analysis
each confirmed the removal of all three terminal
galactose residues.27 Biodistribution analysis of
radioiodinated Tri-CWK18 and agalactosyl-Tri-
CWK18 established the liver as the major target
site, resulting in a 30-min liver targeting effi-
ciency (percent of dose in the target organ) of 1.3
± 0.1% for agalactosyl-Tri-CWK18 versus 52.9 ±
3.5% determined for Tri-CWK18 (not shown).
These results are in close agreement with similar
biodistribution studies on triantennary tyrosin-
amide oligosaccharides,36,37 establishing the re-
quirement for galactose to mediate ASGP-R rec-
ognition of Tri-CWK18.
Plasmid DNA was radiolabeled with 125I to
generate a DNA probe to determine the fate of i.v.
dosed gene delivery formulations. Pharmacoki-
netic analysis of uncondensed plasmid DNA es-
tablished its rapid removal from the circulation
following i.v. dosing with less than 30% of the
dose remaining in the blood after 1 min (Figure
2A). Electrophoretic analysis of the DNA remain-
ing in blood established it was completely frag-
mented within 6 min (Figure 2A8) indicating that
the majority of the pharmacokinetic profile repre-
sented elimination of metabolites. The analysis of
AlkCWK18 and Tri-CWK18 DNA condensates es-
tablished a similar profile of rapid elimination
(Figure 2B,C) and formation of metabolites
within 6 min (Figure 2B8,C8) suggesting that nei-
ther AlkCWK18 nor Tri-CWK18 significantly pro-
tected DNA from endonucleases either in the se-
rum or tissues.
Biodistribution analysis of i.v. dosed plasmid
DNA, AlkCWK18, and Tri-CWK18 DNA conden-
sates established the liver as the major target site
at 5 min for all three formulations, resulting in a
targeting efficiency of 60% for plasmid DNA, 48%
for AlkCWK18 DNA condensates, and 57% for Tri-
CWK18 DNA condensates (Figure 3A) with all
other organs possessing <7% of the 125I-DNA
dose. A similar biodistribution profile was ob-
served at 15 and 30 min for each formulation with
proportional decreases in the liver targeting over
time without significant increases in the distribu-
tion to other tissues (Figure 3B,C).
The biodistribution time was extended to 2 h to
examine the half-life of 125I-DNA in the liver.
Plasmid DNA was rapidly eliminated from the
liver with a t1/2 of 0.61 h, resulting in only 7% of
the radioactive dose remaining in the liver after 2
h (Figure 4A). AlkCWK18 DNA condensates and
Tri-CWK18 DNA condensates were also rapidly
eliminated from the liver with a similar t1/2 of 0.8
and 0.63 h, respectively (Figure 4B,C). These re-
sults suggested that either AlkCWK18 and Tri-
CWK18 DNA condensates dissociate during circu-
lation or they fail to significantly protect DNA
from metabolism in the liver.
If stable during circulation, AlkCWK18 and Tri-
CWK18 DNA condensates would likely produce
altered cell-type specific targeting in the liver
relative to plasmid DNA. Therefore, the cellular
distribution of 125I-DNA in the liver was investi-
gated by separating hepatocytes and Kupffer cells
following collagenase perfusion. Plasmid DNA
distributed with 65% to Kupffer cells and 35% to
hepatocytes while AlkCWK18 DNA condensates
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produced a nearly identical distribution with 68%
associated with Kupffer cells and 32% with hepa-
tocytes (Table 1). These data supported a hypoth-
esis involving the rapid serum dissociation of
AlkCWK18 DNA condensates with subsequent
biodistribution of plasmid DNA. Analysis of Tri-
CWK18 DNA condensates established a slight im-
provement in the cell-type specific targeting with
55% distributed to Kupffer cells and 45% to he-
patocytes, providing some evidence that Tri-
CWK18 DNA condensates are at least partially
stable during circulation and facilitate some rec-
ognition by the ASGP-R (Table 1).
The short half-life of DNA condensates in the
liver also suggested that little or no metabolic
protection was afforded using LMW DNA carriers
(Figure 4A–C). To determine if this was only
true of LMW carriers, the biodistribution of a
HMW polylysine1007 DNA condensate was ana-
lyzed since it is less likely to dissociate during
circulation and is reportedly more resistant to
in vitro DNA metabolism than AlkCWK18 DNA
condensates.30 Even though polylysine1007 and
AlkCWK18 DNA condensates were similar in par-
ticle size and zeta potential (Table 2), polyly-
sine1007 DNA condensates biodistributed with
only 25% associated with the liver and 25% in
lung after 5 min. The longer liver elimination t1/2
of 2.8 h implied that polylysine1007 DNA conden-
sates were intact in the liver (Table 1). Presum-
ably, polylysine1007 DNA condensates are rapidly
opsonized during circulation due to their electro-
positive surface charge (Table 2), causing their
biodistribution to the lung. The fact that there
Figure 1. Structure of Tri-CWK18, agalactosyl-Tri-CWK18, PEG-CWK18, and
AlkCWK18. The chemical structure of each LMW DNA carrier used is illustrated. Each
carrier shares a common 20 amino acid peptide (CWK18) but differs in the structure
attached to the cysteine residue.
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was minimal lung targeting associated with
AlkCWK18 DNA condensates supports the hy-
pothesis that these dissociate during circulation.
Notably, 54% of the polylysine1007
125I-DNA con-
densate recovered in the liver was associated with
Kupffer cells, whereas 46% was with hepatocytes
(Table 1). This result established that both elec-
tronegative plasmid DNA and electropositive
HMW polylysine DNA condensates produce a
similar nonspecific cell-type distribution when
Figure 2. Pharmacokinetic Analysis of 125I-DNA and 125I-DNA condensates. Plasmid
DNA (A), AlkCWK18 DNA (B), and Tri-CWK18 DNA condensates (C) (5 mg) were dosed
i.v. in triplicate mice and 10-mL blood samples were drawn at times ranging from 1 to
60 min. Direct g-counting of blood time points resulted in the pharmacokinetic profiles
plotted as the mean ± standard deviation versus sampling time in A–C. Following
extraction from blood time points, DNA samples were resolved by agarose gel electro-
phoresis and detected by autoradiography to establish the DNA morphology as super-
coiled (sc), circular (cir), or fragmented as illustrated in A8, B8, and C8. The results
indicate that plasmid DNA and condensed DNA is quickly cleared from the circulation
and metabolized into DNA fragments within 6 min following i.v. dosing.
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taken up by the liver. Collectively, these results
supported the hypothesis that the primary differ-
ence between polylysine1007 and AlkCWK18 DNA
condensates was their stability during circula-
tion.
To overcome the short elimination half-life of
LMW peptide DNA condensates, glutaraldehyde
was used to crosslink and stabilize DNA conden-
sates as reported previously.30 Note that cross-
linking Tri-CWK18 or PEG-CWK18 DNA conden-
sates required higher glutaraldehyde concentra-
tions (6–15 mol eq) to achieve equivalent stability
to AlkCWK18 DNA condensates (4 mol eq) as de-
termined by the salt sonication gel electrophore-
sis assay.30 The crosslinked DNA condensates
were utilized without removing residual glutaral-
dehyde and afford stabilized DNA condensates
that maintained particle size for up to 1 week
when stored at 4°C.
Crosslinked AlkCWK18 DNA condensates were
similar in size (50 nm) and charge (+34 mV) to
HMW polylysine DNA condensates (Table 2).
However when dosed i.v., 70% of the dose accu-
mulated in the lung at 2 h with less then 1% re-
Figure 3. Biodistribution of 125I-DNA and 125I-DNA
condensates in mice. Quantitative biodistribution was
performed by direct g-counting of dissected tissues at 5
(A), 15 (B), and 30 min (C) following jugular vein dosing
in triplicate mice. The targeting efficiency (percent of
dose in the organ) was determined for plasmid 125I-
DNA, AlkCWK18, and Tri-CWK18
125I-DNA conden-
sates (2.5-mg dose) in the tissues indicated. The data
represent the mean and standard deviation of triplicate
mice.
Figure 4. Liver targeting efficiency and elimination
of 125I-DNA and 125I-DNA condensates. The radioactiv-
ity in the liver was determined by g-counting as a func-
tion of time after dosing plasmid 125I-DNA (A),
AlkCWK18
125I-DNA condensates (B), Tri-CWK18
125I-
DNA condensates (C), crosslinked (6 mol eq) Tri-
CWK18
125I-DNA condensates (D), crosslinked (15 mol
eq) Tri-CWK18/PEG-CWK18 (50:50)
125I-DNA conden-
sates (E), crosslinked (15 mol eq) agalactosyl-Tri-
CWK18/PEG-CWK18 (50:50)
125I-DNA condensates (F),
crosslinked (15 mol eq) Tri-CWK18/PEG-CWK18 (10:90)
125I-DNA condensates (G), crosslinked (15 mol eq) aga-
lactosyl-Tri-CWK18/PEG-CWK18 (10:90)
125I-DNA con-
densates (H), and crosslinked PEG-CWK18 (15 mol eq)
125I-DNA condensates (I). The data represents the
mean and standard deviation for 3 mice at each time
point.
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covered from the liver. These results further sup-
port the hypothesis that uncrosslinked AlkCWK18
DNA condensates dissociate during circulation,
and that once stabilized by crosslinking, the elec-
tropositive surface charge results in rapid opso-
nization and significant lung targeting.
Crosslinked Tri-CWK18 DNA condensates also
possessed a mean diameter of 56 nm and a
slightly reduced zeta potential of +20 mV (Table
2). However when dosed i.v., 59% of crosslinked
Tri-CWK18 DNA condensates targeted the liver at
5 min followed by elimination with a t1/2 of 2.6 h,
such that 38% of the dose remained in the liver
at 2 h (Figure 4D). In contrast to crosslinked
AlkCWK18 DNA condensates, crosslinked Tri-
CWK18 DNA condensates avoided targeting to the
lung, suggesting that the triantennary oligosac-
charide is sufficient to block opsonization of DNA
condensates in the blood. Despite the decrease in
the liver elimination rate afforded by crosslink-
ing, the cell-type specific targeting was only mod-
estly improved over uncrosslinked Tri-CWK18
DNA condensates, resulting in 45% targeting to
Kupffer cells and 55% to hepatocytes (Table 1).
These results suggested that the remaining posi-
tive charge on crosslinked Tri-CWK18 DNA con-
densates may be responsible for the nonspecific
targeting to Kupffer cells.
A further reduction in the surface charge of
DNA condensates may improve the hepato-
cyte targeting of Tri-CWK18 DNA condensates
by masking their detection by Kupffer cells.
Other gene delivery systems accomplish this by
precisely titrating HMW carriers with DNA to
form condensates having neutral or negative
charge.15,16,22 This strategy is not suitable for the
LMW carriers since these require crosslinking to
remain intact during circulation, and glutaralde-
hyde crosslinking requires the presence of excess
amine groups on DNA for the formation of Schiff-
bases.30
An alternative approach is to mask the surface
charge of DNA condensates by incorporating
PEG-CWK18 as previously demonstrated by the
formation of PEG-CWK18/AlkCWK18 DNA co-
condensates.29 In this study, PEG-CWK18 and
Tri-CWK18 were admixed and used to prepare
DNA co-condensates as shown in Scheme 1. Tri-
CWK18/PEG-CWK18 (50 mol %) DNA co-conden-
sates crosslinked with 15 mol eq of glutaralde-
hyde were 39 nm in diameter and possessed a
zeta potential of +5 mV (Table 2). The ratio of
Tri-CWK18 and PEG-CWK18 bound to DNA in co-
condensates was nearly the same as the admix
ratio used to condense DNA as revealed by glu-












A 159 ± 57 251 ± 37 0.56 35 65 0.6
B 264 ± 53 522 ± 190 0.50 32 68 0.8
C 188 ± 48 211 ± 63 0.81 45 55 0.6
D 540 ± 108 394 ± 19 1.25 55 45 2.6
E 1161 ± 205 259 ± 33 4.50 80 20 2.1
F 526 ± 202 374 ± 76 1.40 55 45 2.5
G 922 ± 320 198 ± 41 4.63 80 20 3.6
H 573 ± 232 434 ± 139 1.29 54 46 2.4
I 477 ± 128 424 ± 224 1.20 53 47 2.4
J 416 ± 26 446 ± 34 0.93 46 54 2.8
K 762 ± 79 174 ± 27 4.47 80 20 4.7
L 1228 ± 40 403 ± 57 3.10 73 27 n.d.
a Dosage form dosed i.v.: A 4 Plasmid 125I-DNA; B 4 AlkCWK18
125I-DNA; C 4 Tri-CWK18
125I-DNA; D 4 crosslinked (6 mol
eq) Tri-CWK18
125I-DNA; E 4 crosslinked (15 mol eq) Tri-CWK18/PEG-CWK18 (50:50)
125I-DNA; F 4 crosslinked (15 mol eq)
Agalactosyl-Tri-CWK18/PEG-CWK18 (50:50)
125I-DNA; G 4 crosslinked (15 mol eq) Tri-CWK18/PEG-CWK18 (10:90)
125I-DNA; H 4
crosslinked (15 mol eq) Agalactosyl-Tri-CWK18/PEG-CWK18 (10:90)
125I-DNA; I 4 crosslinked (15 mol eq) PEG-CWK18
125I-DNA;
J 4 polylysine1007
125I-DNA; K 4 crosslinked (15 mol eq) Tri-CWK18/PEG-CWK18 (2:98)
125I-DNA; L 4 crosslinked (15 mol eq)
Tri-CWK18/PEG-CWK18 (10:90)
125I-DNA, 1 mL tail vein.
b Mean cpm per 106 hepatocytes with standard deviation (n 4 3).
c Mean cpm per 105 Kupffer cells with standard deviation (n 4 3).
d Calculated as the cpm ratio of hepatocytes (106)/Kupffer cells (105).
e Calculated as the percent of cpm in either hepatocytes (106) or Kupffer cells (105) over total.
f Calculated by ln C0 4 ln C − kt, t1/2 4 0.693/k, assuming first-order kinetics from Cmax.
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cosamine analysis which recovered 96% of the
Tri-CWK18 after prolonged dialysis.
Biodistribution analysis of crosslinked Tri-
CWK18/PEG-CWK18 DNA co-condensates re-
sulted in a lag in the liver accumulation of radio-
activity that peaked at 61% of the dose at 30 min
followed by elimination with a t1/2 of 2.1 h result-
ing in 37% remaining in the liver at 2 h (Figure
4E). As predicted, the cell-type specific targeting
was dramatically improved with only 20% recov-
ered in the Kupffer cells and 80% in hepatocytes,
demonstrating the ability of PEG to mask the sur-
face charge of DNA condensates reducing their
nonspecific recognition by liver Kupffer cells.
As a negative control, crosslinked agalactosyl-
Tri-CWK18/PEG-CWK18 DNA co-condensates
were studied. The liver targeting efficiency was
similar to otherwise identical DNA condensates
containing Tri-CWK18, also resulting in an elimi-
nation t1/2 of 2.5 h (Figure 4F). However, only 55%
of the liver targeted DNA was recovered in hepa-
tocytes whereas 45% was found in Kupffer cells,
establishing that terminal galactose residues on
Tri-CWK18 are responsible for approximately
25% of the cell-type specific targeting of these
DNA condensates.
To determine if the admix ratio could be ad-
justed to further reduce the amount of Tri-CWK18
without compromising target site selectivity, bio-
distribution studies were conducted using a 10:90
admix ratio of crosslinked Tri-CWK18/PEG-
CWK18 DNA co-condensates. The liver targeting
efficiency reached approximately 61% in 15 min
and remained at 57% at 30 min and was then
eliminated with a t1/2 of 3.6 h, resulting in 44% of
the dose in the liver after 2 h (Figure 4G). A con-
trol, in which agalactosyl-Tri-CWK18 was substi-
tuted for Tri-CWK18 had a similar liver biodis-
tribution profile with an elimination t1/2 of 2.4 h
(Figure 4H). As was the case for condensates pre-
pared with 50:50 Tri-CWK18/PEG-CWK18, 80% of
the 125I-DNA was recovered in hepatocytes when
using Tri-CWK18 whereas only 54% was in hepa-
tocytes using agalactosyl-Tri-CWK18. Further ex-
periments established that as little as 2 mol % of
Tri-CWK18 admixed with 98% PEG-CWK18
formed crosslinked DNA co-condensates that me-
diated a targeting efficiency of 53% in the liver at
30 min of which 80% was recovered in hepato-
cytes (Table 1).
A final set of control studies examined the bio-









B 81 33 ± 5
C 107 30 ± 6
D 56 20 ± 1
E 39 5 ± 3
F 72 6 ± 3
G 38 3 ± 2
H 49 6 ± 1
I 86 2 ± 1
J 36 38 ± 5
K 44 5 ± 5
L 50 34 ± 4
a Each prepared at 0.4 nmol of peptide per mg of DNA.
b Dosage form dosed i.v.: A 4 Plasmid DNA; B 4
AlkCWK18 DNA; C 4 Tri-CWK18 DNA; D 4 crosslinked (6
mol eq)Tri-CWK18 DNA; E 4 crosslinked (15 mol eq) Tri-
CWK18/PEG-CWK18 (50:50) DNA; F 4 crosslinked (15 mol eq)
Agalactosyl-Tri-CWK18/PEG-CWK18 (50:50) DNA; G 4
crosslinked (15 mol eq) Tri-CWK18/PEG-CWK18 (10:90) DNA;
H 4 crosslinked (15 mol eq) Agalactosyl-Tri-CWK18/PEG-
CWK18 (10:90) DNA; I 4 crosslinked (15 mol eq) PEG-CWK18
DNA; J 4 polylysine1007 DNA; K 4 crosslinked (15 mol eq)
Tri-CWK18/PEG-CWK18 (2:98) DNA; L 4 crosslinked (6 mol
eq) AlkCWK18 DNA.
c Particle size reported as the mean diameter of a major
(90%) smaller diameter (30–40 nm) population and a minor
(10%) larger diameter population (110–130 nm).
d Mean and standard deviation of 10 measurements.
Scheme 1. Formulation of Crosslinked Tri-CWK18/
PEG-CWK18 Co-condensates. Tri-CWK18 and PEG-
CWK18 were admixed at either a 50:50, 10:90, or 2:98
mol %, and were then used to form DNA co-conden-
sates. After 30 min, DNA co-condensates were cross-
linked with 15 mol eq of glutaraldehyde.
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distribution of crosslinked 100 mol % PEG-
CWK18 DNA condensates. The liver was still the
major target site with approximately 58% of the
dose taken up in 5 min and an elimination t1/2 of
2.4 h (Figure 4I). Interestingly, 53% of the liver
target DNA was recovered in the hepatocyte frac-
tion whereas the remaining 47% was associated
with Kupffer cells (Table 1). These results indi-
cated that even without incorporating a targeting
ligand, crosslinked PEG-CWK18 DNA conden-
sates are still taken up through a nonspecific pro-
cess by both Kupffer cells and hepatocytes.
Crosslinked DNA co-condensates were also
evaluated for their ability to mediate hAAT ex-
pression in vivo. A 1-mL dose containing 50 mg of
DNA condensates was administered via slow in-
fusion into the tail vein of mice. The large dosing
volume was used to ensure a small particle size
since concentrations above 100 mg/mL result in
larger particles.29 However, when PEG-CWK18 is
included at 98 mol % of the admix ratio, small
particles (<100 nm) can be maintained at high
concentrations (2 mg/mL),29 which will allow the
dosing volume to be reduced and systematically
explored in future studies. Even when dosing 50
mg of DNA, biodistribution studies using an 125I-
DNA tracer established a 2-h liver targeting effi-
ciency of 36% with 73% recovered in hepatocytes,
suggesting the 50-mg dose did not saturate the
ASGP-R (Table 1).
Analysis of the transient gene expression pro-
file of hAAT after i.v. dosing 50 mg of crosslinked
Tri-CWK18/PEG-CWK18 (10:90) DNA co-conden-
sates demonstrated a peak in the expression at
day 7 at 6 ng/mL that returned to a baseline lev-
els by day 9 (Figure 5). Similar analysis of aga-
lactosyl-Tri-CWK18/PEG-CWK18 (10:90) DNA co-
condensates established the complete lack of gene
expression which was an identical result to a con-
trol using plasmid DNA (Figure 5).
DISCUSSION
The development of a therapeutically useful non-
viral gene delivery formulation will require sys-
tematic optimization of the DNA carrier complex
to achieve maximum targeting selectivity and
gene expression. The present study has at-
tempted to establish correlations between the
composition of the carrier components bound to
plasmid DNA and the targeting efficiency to he-
patocytes in mice with the aim of determining if
LMW carriers can be used to mediate gene trans-
fer in vivo. No other previous studies have re-
ported the in vivo use of LMW peptides as substi-
tute DNA carriers for HMW conjugates despite
the importance of reducing the molecular weight
and heterogeneity of these biomolecules in order
to avoid unwanted side effects.
The results clearly indicate that a LMW carrier
by itself is not sufficient to mediate gene targeting
of an i.v. dosed DNA formulation. This is not ob-
vious from a preliminary investigation since 58%
of Tri-CWK18 DNA condensates targeted the liver
after 5 min of biodistribution. However, when
evaluated in light of control experiments demon-
strating that plasmid DNA and AlkCWK18 DNA
condensates also target the liver with very simi-
lar efficiency, it becomes clear that plasmid DNA
is released upon dissociation of LMW carriers
during circulation.
A surprising result was that crosslinked Tri-
CWK18 DNA condensates are not sufficient to
achieve maximum hepatocyte targeting even
though the oligosaccharide used is a potent ligand
for the ASGP-R, possessing a million-fold greater
affinity than galactose.28 Despite the presence of
approximately 700 copies of the triantennary li-
Figure 5. In vivo transient gene expression. Mice
were dosed in the tail vein with 50 mg of plasmid DNA,
and the hAAT produced over a 10-day period was de-
termined by ELISA. The transient gene expression pro-
file is presented for crosslinked (15 mol eq) Tri-CWK18/
PEG-CWK18 (10:90) DNA condensates (d), crosslinked
(15 mol eq) agalactosyl-Tri-CWK18/PEG-CWK18 (10:90)
DNA condensates (j), as well as plasmid DNA (m).
Each data point represents the mean and standard er-
ror for 3–6 mice. Comparison of hAAT expression levels
on day 7 to levels on day 1 or day 10 established sta-
tistical significance (P < 0.025).
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gand per 6.9 kb plasmid, the electropositive
charge of crosslinked Tri-CWK18 DNA conden-
sates is apparently still detected by Kupffer cells.
It is also interesting to note that crosslinked Tri-
CWK18 DNA condensates did have significantly
altered biodistribution in comparison to HMW
polylysine and crosslinked AlkCWK18 DNA con-
densates of comparable size and charge. The pres-
ence of the triantennary N-glycan allowed these
DNA condensates to avoid lung targeting, pre-
sumably by blocking opsonization in the serum.
Only after incorporating both PEG-CWK18 and
Tri-CWK18 into DNA condensates could specific
recognition by hepatocytes be achieved. This
closely correlated with a decreased zeta poten-
tial, indicating that PEG functioned to block
Kupffer cell recognition by masking the surface
charge of Tri-CWK18 DNA condensates. The
masking was equally efficient with either 50, 90,
or 98 mol % PEG-CWK18 as indicated by the he-
patocyte targeting efficiency. Moreover, this data
indicates that attachment of as few as 14 copies (2
mol %) of the triantennary oligosaccharide to a
plasmid is sufficient to mediate specific recogni-
tion by the ASGP-R and that the surface bound
PEG does not sterically block ASGP-R recognition
of Tri-CWK18. Using this high-affinity ligand, the
ASGP-R was able to bind DNA co-condensates in
the dosing range of 2.5–50 mg delivered via tail
vein without a significant reduction in target se-
lectivity for hepatocytes (Table 1).
The use of LMW carriers also necessitates the
use of crosslinking agents to stabilize DNA car-
rier condensates. The advantages of this ap-
proach are that LMW carriers can be synthesized,
purified, and structurally characterized, elimi-
nating uncertainty over the stoichiometry or at-
tachment site of ligands to the backbone peptide.
Two or potentially more LMW carriers can be
combined and used to condense DNA to form co-
condensates. Since each LMW carrier contains an
identical cationic peptide, they incorporate into
DNA co-condensates according to their admix ra-
tio29 allowing systematic optimization of the
amount of ligand or PEG bound to DNA conden-
sates.
The disadvantage of LMW carriers is the ne-
cessity for molecular crosslinking. Although this
stabilizes DNA condensates to metabolism,30 the
use of glutaraldehyde results in an overall lower
level of in vitro gene expression which appears
also to be true of in vivo expression. Likewise,
crosslinked LMW carriers may resemble HMW
carriers once they are released inside the cell and
exhibit similar toxicity. To circumvent these prob-
lems, other methods under development could
serve to both transiently stabilize LMW DNA car-
rier condensates and simultaneously enhance the
gene expression level.38–40
As a proof of principle we have demonstrated
that specific targeting to hepatocytes requires the
use of crosslinked Tri-CWK18/PEG-CWK18 DNA
condensates. The metabolic stabilization afforded
by crosslinking is apparent by comparison of the
liver t1/2 of uncrosslinked and crosslinked Tri-
CWK18 DNA condensates (Figure 4). Since reten-
tion of DNA in the target site is an important
prerequisite to sustaining transient gene expres-
sion, the degree of crosslinking may be an adjust-
able parameter to control the time of onset or du-
ration of gene expression.
Incorporating PEG-CWK18 into DNA conden-
sates resulted in a lag of 40–60 min in the peak
accumulation of 125I-DNA in the liver (Figure 4E–
I). Since this lag is not apparent when using un-
crosslinked DNA condensates (Figure 4A–C), it is
unlikely the result of re-distribution and uptake
of metabolized 125I-DNA. It is more likely due to a
slower recognition of the DNA condensate by ei-
ther the asialoglycoprotein receptor when incor-
porating Tri-CWK18 or by the Kupffer cell scav-
enger receptor when substituted with agalacto-
syl-Tri-CWK18.
Comparison of the transient gene expression of
optimized LMW dosage forms with and without
ligand established a dependency on galactose.
The maximal gene expression occurring at day 7
is mostly likely due to the slow release of cross-
linked DNA co-condensates. Although the serum
levels of hAAT are low compared to hepatic portal
vein dosed viral vector delivery systems,41 there
is no reference data regarding the levels of liver
expression of hAAT following i.v. dosing of a viral
delivery systems.
In conclusion, the results presented demon-
strate that it is possible to use a combination of
LMW carrier molecules to achieve cell-type spe-
cific gene delivery and transient gene expression
in mouse liver. The information from this study
should provide a foundation from which to pursue
DNA targeting to organs other than the liver.
Further studies will be needed to optimize LMW
carriers to increase the transient gene expression
levels. This will likely involve the application of
crosslinking strategies designed to release DNA
inside the target cells.37,38
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